Cell therapy improves progression-free survival with 50% in advanced melanoma
At ESMO 2022, the first randomized phase 3 trial to investigate T-cell therapy in solid advanced tumors in patients with advanced melanoma is presented. Results suggest that treatment with tumor-infiltrating lymphocytes (TIL) significantly improves progression-free survival when compared to ipilimumab (IPI). Get the full presentation from Professor John Haanen in this MEDtalk.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.